|
WO2020086112A1
|
|
Multi-channel real-time cardiovascular performance evaluation system and method
|
|
WO2020149846A1
|
|
Methods for predicting major adverse cardiovascular events and/or death in patients with coronary heart disease
|
|
WO2019177671A1
|
|
Targeting txndc5 as a novel diagnostic and therapeutic approach for organ fibrosis and related diseases
|
|
WO2019231443A1
|
|
Marker and method for evaluating cognitive dysfunction
|
|
EP3610033A1
|
|
Method for prognosing and reducing cardiovascular disease in patients with kidney diseases
|
|
WO2018191536A1
|
|
Method for prognosing adverse cardiovascular outcome in patients with coronary artery diseases
|
|
TW201938109A
|
|
Biological marker and method for evaluating mild cognitive impairment based on changes of the blood oxygen concentration of the frontal lobe
|
|
WO2019153198A1
|
|
Application of synthetic vivianite particles as oral iron supplement
|
|
WO2019144412A1
|
|
Use of oral iron particles
|
|
US2019072563A1
|
|
Method for early diagnosing and treating acute coronary syndrome
|
|
TW201912168A
|
|
Application of synthetic vivianite particles as oral iron preparation wherein the oral iron preparation is excipient free
|
|
WO2018227448A1
|
|
Orally-administered poison adsorbent and manufacturing method therefor
|
